Expansion of precision medicine approaches will play a key role in optimizing care and improving outcomes for breast cancer patients in 2017. Here we highlight some of the studies and FDA approvals we are most anxious to see in the coming year.
ONCOLOGY Vol 30 No 12_Suppl_2
Advertisement
Advertisement
Trending on CancerNetwork
1
ASCO Releases New Patient-Clinician Communication Guidelines
2
Melanoma Vaccine Receives FDA Fast Track Designation
3
NCCN Guidelines Recommend Taletrectinib for ROS1+ NSCLC Subtype
4
TERN-701 Earns FDA Breakthrough Therapy Designation in Ph+ CML
5